openPR Logo
Press release

Nonalcoholic Fatty Liver Disease (NAFLD) Market Booming Worldwide With Leading Key Players - Pfizer Inc., AstraZeneca, Novartis AG, Takeda Pharmaceutical Company Limited., Intercept Pharmaceuticals, Inc., F. Hoffmann-La Roche Ag, Merck & Co

07-15-2024 10:37 AM CET | Health & Medicine

Press release from: DataM intelligence 4 Market Research LLP

Nonalcoholic Fatty Liver Disease (NAFLD) Market Booming

DataM Intelligence has published a new research report on "Nonalcoholic Fatty Liver Disease (NAFLD) Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Free Sample Research PDF - https://datamintelligence.com/download-sample/nonalcoholic-fatty-liver-disease-market

The Nonalcoholic Fatty Liver Disease (NAFLD) market report majorly focuses on market trends, historical growth rates, technologies, and the changing investment structure. Additionally, the report shows the latest market insights, increasing growth opportunities, business strategies, and growth plans adopted by major players. Moreover, it contains an analysis of current market dynamics, future developments, and Porter's Five Forces Analysis.

Nonalcoholic fatty liver disease (NAFLD) refers to a spectrum of liver conditions characterized by excessive fat accumulation in the liver of individuals who consume little to no alcohol. It is often associated with obesity, insulin resistance, metabolic syndrome, and other risk factors such as diabetes and high cholesterol levels. NAFLD can range from simple fatty liver (steatosis), which usually causes no symptoms and does not progress, to nonalcoholic steatohepatitis (NASH), a more severe form characterized by inflammation and liver cell damage. NASH can progress to fibrosis, cirrhosis (severe scarring of the liver), and even liver failure or liver cancer in some cases. Management of NAFLD involves lifestyle modifications such as weight loss, dietary changes, regular exercise, and management of underlying conditions like diabetes and high cholesterol. In more severe cases, medications and close monitoring by healthcare providers are necessary to prevent progression and manage complications.

Forecast Growth Projected:

The Global Nonalcoholic Fatty Liver Disease (NAFLD) Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

List of the Key Players in the Nonalcoholic Fatty Liver Disease (NAFLD) Market:

Pfizer Inc., AstraZeneca, Novartis AG, Takeda Pharmaceutical Company Limited., Intercept Pharmaceuticals, Inc., F. Hoffmann-La Roche Ag, Merck & Co., Inc., Abbvie Inc., And Gilead Sciences, Inc. among others.

Segment Covered in the Nonalcoholic Fatty Liver Disease (NAFLD) Market:

By Drug Class: Antioxidants, Lipid-Lowering Drugs, Insulin sensitizers, Pentoxifylline, Angiotensin Receptor Blockers, Others

By Disease Stage: Non-Alcoholic Steatohepatitis (NASH), Cirrhosis, Fibrosis

By Route of Administration: Injectable, Oral, Other

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others

Regional Analysis:

The global Nonalcoholic Fatty Liver Disease (NAFLD) Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.

Get Customization in the report as per your requierments: https://datamintelligence.com/customize/nonalcoholic-fatty-liver-disease-market

Regional Analysis:

The global Nonalcoholic Fatty Liver Disease (NAFLD) Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. The report offers detailed insight into new product launches, new technology evolutions, innovative services, and ongoing R&D. The report discusses a qualitative and quantitative market analysis, including PEST analysis, SWOT analysis, and Porter's five force analysis. The Nonalcoholic Fatty Liver Disease (NAFLD) Market report also provides fundamental details such as raw material sources, distribution networks, methodologies, production capacities, industry supply chain, and product specifications.

Chapter Outline:

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: key insights, key emerging trends, etc.

Chapter 3: Manufacturers competitive analysis, detailed analysis of Nonalcoholic Fatty Liver Disease (NAFLD) manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 5 & 6: Revenue of Nonalcoholic Fatty Liver Disease (NAFLD) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: The main points and conclusions of the report.

Get a Free Sample PDF copy of the report @ https://datamintelligence.com/download-sample/nonalcoholic-fatty-liver-disease-market

Read Latest Blog: https://www.datamintelligence.com/blogs/top-10-process-automation-companies-worldwide

Affiliate Marketing Request here: https://www.datamintelligence.com/affiliate-marketing

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Nonalcoholic Fatty Liver Disease (NAFLD) Market Booming Worldwide With Leading Key Players - Pfizer Inc., AstraZeneca, Novartis AG, Takeda Pharmaceutical Company Limited., Intercept Pharmaceuticals, Inc., F. Hoffmann-La Roche Ag, Merck & Co here

News-ID: 3580415 • Views:

More Releases from DataM intelligence 4 Market Research LLP

Semiconductor & IC Packaging Materials Market to Hit US$ 93.7 Billion by 2031 | CAGR 10.2% | North America Leads with 35% | Key Players: Intel, TSMC, Samsung, ASE, Amkor, Siemens
Semiconductor & IC Packaging Materials Market to Hit US$ 93.7 Billion by 2031 | …
Market Size and Overview The global Semiconductor and IC Packaging Materials Market reached US$ 43.1 billion in 2023 and is projected to grow to US$ 93.7 billion by 2031, registering a CAGR of 10.2% during 2024-2031. The market expansion is driven by the increasing demand for electronic hardware capable of delivering high performance, speed, and bandwidth while maintaining low latency and power consumption. Advanced packaging technologies are meeting these requirements by
Automotive Cybersecurity Market to Hit US$ 12,601.67 million by 2032 | CAGR 18.3% | North America Leads with 30% | Key Players: BlackBerry Limited, Cisco Systems, Infineon, NXP, Argus, CENTRI, Arxan, Lear, Harman, Delphi
Automotive Cybersecurity Market to Hit US$ 12,601.67 million by 2032 | CAGR 18.3 …
The global automotive cybersecurity market reached US$ 3,370.00 million in 2024 and is projected to grow to US$ 12,601.67 million by 2032, registering a robust CAGR of 18.3%. This rapid growth is driven by the increasing adoption of connected and software-defined vehicles (SDVs), which expand the potential attack surface with advanced telematics, infotainment, and driver-assistance systems. In 2024, over 80% of newly sold vehicles in the US featured such technologies,
Beryllium Market to Reach USD 492.01 Million by 2032 | CAGR 7.22% | Aerospace & Defense Lead with 35% Share | Key Players: Materion Corporation, NGK Metals Corp, Kazatomprom, IBC Advanced Alloys
Beryllium Market to Reach USD 492.01 Million by 2032 | CAGR 7.22% | Aerospace & …
Beryllium Market Overview The global beryllium market reached US$ 281.65 million in 2024 and is projected to reach US$ 492.01 million by 2032, growing at a CAGR of 7.22% during the forecast period 2025-2032. The market is witnessing robust growth driven by the expanding use of beryllium across aerospace, defense, electronics, and telecommunications sectors, where its exceptional stiffness-to-weight ratio, high thermal conductivity, and corrosion resistance make it indispensable. Get a Free Sample
United States Hemp Milk Market to Reach USD 153.96 Million by 2030, Growing at a CAGR of 7.1% | Driven by Plant-Based Nutrition Demand Across Asia-Pacific & North America | Key Players - Pacific Foods, Good Hemp, Tilray
United States Hemp Milk Market to Reach USD 153.96 Million by 2030, Growing at a …
Leander, Texas and Tokyo, Japan - Jan.13.2026 Global Hemp Milk Market reached USD 296.5 million in 2022 and is expected to reach USD 513.2 million by 2030 growing with a CAGR of 7.1% during the forecast period 2024-2031. Market growth is driven by rising consumer demand for plant-based and dairy-free beverages, increasing awareness of nutritional benefits such as omega fatty acids and protein content, and growing adoption of vegan and lactose-free

All 5 Releases


More Releases for NAFLD

Nonalcoholic Fatty Liver Disease (NAFLD) Patient Pool Analysis Market to Reach U …
Pune, India - December 2025 - The global Nonalcoholic Fatty Liver Disease (NAFLD) Patient Pool Analysis Market, valued at USD 1.67 billion in 2024, is projected to reach USD 2.94 billion by 2034, growing at a 5.8% CAGR (2025-2034), according to Exactitude Consultancy. The rapid rise in obesity, type 2 diabetes, metabolic syndrome, and expanded liver health screening are increasing NAFLD patient identification worldwide. Download Full PDF Sample Copy of Market
Nonalcoholic Fatty Liver Disease (NAFLD) Patient Pool to Reach 1.7 Billion by 20 …
Nonalcoholic fatty liver disease (NAFLD) has emerged as one of the most pressing global health challenges of the 21st century. Characterized by the accumulation of fat in the liver not caused by alcohol consumption, NAFLD is closely associated with obesity, type 2 diabetes, and metabolic syndrome. In its severe form, nonalcoholic steatohepatitis (NASH), the disease can progress to cirrhosis, liver failure, or hepatocellular carcinoma, making it a major cause of
Non-Alcoholic Fatty Liver Disease (NAFLD) Market Detailed Industry Report Analys …
Introduction Non-Alcoholic Fatty Liver Disease (NAFLD) has emerged as one of the most pressing global health challenges of the 21st century. Closely linked to the growing prevalence of obesity, type 2 diabetes, and metabolic syndrome, NAFLD is now the most common liver disorder worldwide. It ranges from simple fat accumulation in the liver (steatosis) to the more severe inflammatory stage known as Non-Alcoholic Steatohepatitis (NASH), which can progress to fibrosis, cirrhosis,
Non-Alcoholic Fatty Liver Disease (NAFLD) Market to Rise at 5.98% CAGR, Reaching …
BREAKING: The Non-Alcoholic Fatty Liver Disease NAFLD market is positioned to become the #1 game-changing force in the global Healthcare sector by 2035, creating unprecedented growth opportunities for manufacturers, technology providers, enterprise clients, solution developers and strategic investors worldwide. This exclusive deep-dive report delivers comprehensive analysis of the rapidly evolving Non-Alcoholic Fatty Liver Disease NAFLD industry, uncovering breakthrough technological advancements, critical market milestones and transformative future projections. It explores the revolutionary
Non Alcoholic Fatty Liver Disease (NAFLD) Market to Witness Growth by 2032, Esti …
DelveInsight's "Non Alcoholic Fatty Liver Disease (NAFLD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Non Alcoholic Fatty Liver Disease (NAFLD), historical and forecasted epidemiology as well as the Non Alcoholic Fatty Liver Disease (NAFLD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Non Alcoholic Fatty Liver Disease (NAFLD) market report provides current treatment practices, emerging drugs,
Panthera leads the way in the UK with specialist research sites for NASH and NAF …
With access to leading hepatologists, biopsy theatres, fibroscans at specialist sites and ongoing mass screening programmes Panthera can help pharma and CROs find a treatment for this increasingly common, progressive, and life-threatening diseases. Non-Alcoholic steatohepatitis NASH and Non-Alcoholic Fatty liver Disease NAFLD have no approved medical treatments to treat these inflammatory conditions. Panthera is already involved with two trials with several more in the pipeline. There are over a thousand studies* underway